Becton, Dickinson and Company (BDX)

Check out top investors' recommendation for BDX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company’s BD Medical segment produces medical devices that are used in various healthcare settings. This segment’s products include needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles used in treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; and closed-system transfer devices. Its BD Diagnostics segment provides products for the collection and transport of diagnostics specimens; and instrument systems and reagents to detect various infectious diseases, healthcare-associated infections, and cancers. This segment’s products comprise integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems; rapid diagnostic assays; microbiology laboratory automation; and plated media. The company’s BD Biosciences segment offers research and clinical tools that facilitate the study of cells and their components. This segment’s products include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; cell imaging systems; laboratory products for tissue culture and fluid handling; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. Becton, Dickinson and Company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Brandon Couillard Jefferies & Co. Buy   Aug 22, '17     230.00  Aug 22, '18  N/A 
Doug Schenkel Cowen And Company Buy   Aug 14, '17     230.00  Aug 14, '18  N/A 
Rick Wise Stifel Nicolaus & Company, Inc. Buy   Aug 03, '17     220.00  Aug 03, '18  N/A 
William Quirk Piper Jaffray Buy   Jul 18, '17     213.00  Jul 18, '18  N/A 
Brandon Couillard Jefferies & Co. Buy   Jul 18, '17     230.00  Jul 18, '18  N/A 
Doug Schenkel Cowen And Company Buy   Jul 10, '17     230.00  Jul 10, '18  N/A 
Lawrence Keusch Raymond James Buy   Jun 30, '17     226.00  Jun 30, '18  N/A 
David Toung Argus Research Company Buy   Oct 21, '16     185.00  Oct 21, '17  N/A 
Amit Bhalla Citi Sell   Sep 23, '16     165.00  Sep 23, '17  N/A 
Doug Schenkel Cowen And Company Buy   Aug 16, '16     185.00  Aug 16, '17  N/A 
Jon Wood Jefferies & Co. Buy   Jul 28, '16     192.00  Jul 28, '17  N/A 
Derik De Bruin BofA Merrill Lynch Buy   May 12, '16   164.49  180.00  May 12, '17  12.38% 
Greg Poole Deutsche Bank Securities Buy   Feb 11, '16   133.12    Feb 11, '17  N/A 
Kristen Stewart Deutsche Bank Securities Buy   Feb 11, '16   133.12  163.00  Feb 11, '17  33.74% 
David Toung Argus Research Company Buy   Jan 07, '16   142.17  167.00  Jan 07, '17  18.09% 
Brian Weinstein William Blair & Company, L.L.C. Buy   Nov 18, '15   149.08    Nov 18, '16  16.33% 
David Toung Argus Research Company Buy   Aug 19, '15   144.03  167.00  Aug 19, '16  20.60% 
David Toung Argus Research Company Buy   Feb 11, '15   139.44  156.00  Feb 11, '16  9.99% 
Doug Schenkel Cowen And Company Buy   Jan 21, '15   140.44    Jan 21, '16  0.30% 
Lawrence Keusch Raymond James Buy   Jan 05, '15   138.35  165.00  Jan 05, '16  6.94% 
< previous12